Genetic Analysis AS

GEAN · Nasdaq Stockholm · Healthcare

0.50NOK −5.7%last day

Price as of 1 October 2026

The price over the past year, with dividends: −43.2%

Performance

1 month

−13.2%

1 year

−43.2%

3 years, per year

−31.8%

5 years, per year

–

Largest fall, 3 years

−96.1%

Below the peak now

−95.9%

Volatility, 1 year

83.8%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

1.7

Dividend yield

0.0%

Return on equity

−62.4%

Net margin

−105.3%

Market value

4 m USD

Quality, value and trend

Where Genetic Analysis stands against every Nordic stock today. 100 is best.

Quality29

Profitability and a sound balance sheet over time. Better than 29% of Nordic stocks.

Value23

The price measured against earnings, assets and cash flow. Better than 23% of Nordic stocks.

Trend10

The price development over the past year. Better than 10% of Nordic stocks.

Combined5

Quality, value and trend together. Better than 5% of Nordic stocks.

About Genetic Analysis

Genetic Analysis AS is a company in healthcare, listed on Nasdaq Stockholm. The share trades in NOK. It has around 18 employees.

Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome research assay; GA-map Sample Collection Kit for the collection, transport, and storage of fecal specimens for nucleic acid analysis; GA-map IBD Precision Dx, a biomarker for inflammatory bowel disease; and GA-map COVID-19 Feca…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis